Trial Profile
A Randomized, Open-Labeled, Multi-Center Study to Investigate the Safety and Efficacy of OROS Hydromorphone HCl Comparing With Morphine SR in Cancer Pain Patients
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 14 Aug 2013
Price :
$35
*
At a glance
- Drugs Hydromorphone (Primary) ; Morphine
- Indications Cancer pain
- Focus Therapeutic Use
- Sponsors Johnson & Johnson
- 09 Aug 2013 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 09 Jan 2010 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.
- 09 Jan 2010 Actual initiation date (Aug 2008) added as reported by ClinicalTrials.gov.